{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:22Z","timestamp":1780988002161,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Brentuximab vedotin (BV)-based combinations have shown promising results in patients with relapsed or refractory Hodgkin\u2019s lymphoma (RRHL) in Western countries. We conducted a phase II study to further define the role of BV-based salvage therapy in transplant-eligible patients with RRHL in Korea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Transplant-eligible patients with RRHL were recruited to receive two cycles of BV (1.8\u00a0mg\/kg) plus DHAP (cisplatin 100\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , cytarabine 2\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and dexamethasone 40\u00a0mg). Autologous stem cells were collected from non-progressive patients who received one more cycle of BV-DHAP. After three cycles, the responding patients underwent autologous stem cell transplantation (ASCT). The primary endpoint was a complete metabolic response (CMR) rate after two cycles of BV-DHAP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between April 2022 and August 2024, seven lymphoma cases were recruited. Owing to slow accrual, the study was terminated early. Their median age was 30\u00a0years (range, 24\u201362\u00a0years). All patients received at least two cycles of BV-DHAP; the overall response rate (ORR) was 100%, and four patients showed CMR (57%). One patient withdrew consent after the second cycle, and the other six patients received one more cycle of BV-DHAP, resulting in five patients achieving CMR (71%). One patient failed to receive ASCT, and all five patients who received ASCT achieved post-transplant CMR with a 80% complete response (CR) over a 12-month duration. Thrombocytopenia was the most common grade 3 or higher grade hematologic adverse events (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095). Grade 2 nausea occurred in three patients. Three patients experienced dose reduction, and four patients experienced treatment delays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite its encouraging early efficacy, the administration of BV-DHAP in Korean patients with RRHL requires careful monitoring due to toxicity concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-025-00097-z","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:14:00Z","timestamp":1763738040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"60","author":[{"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwai Han","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"97_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2022-162780","volume":"140","author":"S Luminari","year":"2022","unstructured":"Luminari S, Foss\u00e5 A, Trotman J, et al. Long follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial (CRUK\/07\/033) confirms the safety of both de-escalation and intensification of chemotherapy. Blood. 2022;140:766\u20137.","journal-title":"Blood"},{"key":"97_CR2","doi-asserted-by":"crossref","unstructured":"Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013;2013:Cd009411.","DOI":"10.1002\/14651858.CD009411.pub2"},{"key":"97_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"97_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bjh.12824","volume":"165","author":"RD Gentzler","year":"2014","unstructured":"Gentzler RD, Evens AM, Rademaker AW, et al. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2014;165:793\u2013800.","journal-title":"Br J Haematol"},{"key":"97_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12885-021-08225-5","volume":"21","author":"K Noring","year":"2021","unstructured":"Noring K, Carlsten M, Sonnevi K, Wahlin BE. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. BMC Cancer. 2021;21:500.","journal-title":"BMC Cancer"},{"key":"97_CR6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812\u201321.","journal-title":"N Engl J Med"},{"key":"97_CR7","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"97_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5045\/br.2023.2023206","volume":"58","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Do YR, Lee HS, et al. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803\/bravo study. Blood Res. 2023;58:194\u2013200.","journal-title":"Blood Res"},{"key":"97_CR9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","volume":"131","author":"GL Shah","year":"2018","unstructured":"Shah GL, Moskowitz CH. Transplant strategies in relapsed\/refractory Hodgkin lymphoma. Blood. 2018;131:1689\u201397.","journal-title":"Blood"},{"key":"97_CR10","doi-asserted-by":"crossref","unstructured":"Hoppe RT, Advani RH, Ai WZ, et al. NCCN Guidelines\u00ae insights: Hodgkin lymphoma, Version 2.2022. J Natl Compr Canc Netw 2022;20:322\u201334.","DOI":"10.6004\/jnccn.2022.0021"},{"key":"97_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1471-2407-9-141","volume":"9","author":"P Pahwa","year":"2009","unstructured":"Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA, McDuffie HH. Ethnicity and incidence of Hodgkin lymphoma in Canadian population. BMC Cancer. 2009;9:141.","journal-title":"BMC Cancer"},{"key":"97_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"97_CR13","doi-asserted-by":"crossref","unstructured":"Hagenbeek A, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu RD, Burggraaf CN, Nijland M, Tonino SH, van Tinteren H, Lopez Yurda MI, Kersten MJ.\u00a0Combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study. Blood. 2018;132(Supplement 1):2923.","DOI":"10.1182\/blood-2018-99-112235"},{"key":"97_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143\u201351.","journal-title":"Biometrics"},{"key":"97_CR15","doi-asserted-by":"publisher","first-page":"1392653","DOI":"10.3389\/fonc.2024.1392653","volume":"14","author":"AF Cashen","year":"2024","unstructured":"Cashen AF. The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma. Front Oncol. 2024;14:1392653.","journal-title":"Front Oncol"},{"issue":"14","key":"97_CR16","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1080\/10428194.2021.1957865","volume":"62","author":"WJ Plattel","year":"2021","unstructured":"Plattel WJ, Bergamasco A, Trinchese F, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2021;62(14):3320\u201332.","journal-title":"Leuk Lymphoma."},{"key":"97_CR17","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2024-211527","volume":"144","author":"AM Sureda Balar\u00ed","year":"2024","unstructured":"Sureda Balar\u00ed AM, Nu\u00f1ez Cespedes J, Terol Castera MJ, et al. The addition of brentuximab vedotin to ESHAP significantly increases the rate of metabolic complete remissions vs chemotherapy alone in patients with relapsed\/refractory classical Hodgkin\u2019s lymphoma. Final results of a phase IIb prospective randomized clinical trial (BRESELIBET). Blood. 2024;144:3049.","journal-title":"Blood"},{"key":"97_CR18","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2024-206047","volume":"144","author":"RC Lynch","year":"2024","unstructured":"Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide (ICE) in second line treatment of relapsed\/refractory classical Hodgkin lymphoma: 5-year long term follow up. Blood. 2024;144:3043.","journal-title":"Blood"},{"issue":"1","key":"97_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40\u20138.","journal-title":"Blood."},{"key":"97_CR20","doi-asserted-by":"crossref","unstructured":"Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study. 2021;106(4):1129\u201337.","DOI":"10.3324\/haematol.2019.243238"},{"key":"97_CR21","doi-asserted-by":"crossref","unstructured":"Huang J, Pang WS, Lok V, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. 2022;15(1):57.","DOI":"10.1186\/s13045-022-01281-9"},{"key":"97_CR22","doi-asserted-by":"crossref","unstructured":"Ogura M, Tobinai K, Fau - Hatake K, Hatake K, Fau - Ishizawa K, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840\u20136","DOI":"10.1111\/cas.12435"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00097-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00097-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00097-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:14:03Z","timestamp":1763738043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00097-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00097-z","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}